Winter Storm Update – MSK is fully operational. Read more

More Information: Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

SK-N-BE(2): Human Neuroblastoma Cell Line (ATCC CRL-2271)



SK-N-BE(2) is a neuroblastoma cell line that displays MYCN amplification. These cells have moderate dopamine-b-hydroxylase activity and low-choline acetyltransferase activity. The SK-N-BE(2) cells are known to form tumors in immunocompromised mice.


This cell line was established in 1972 from a metastatic site (bone marrow) in a two-year-old Caucasian male with malignant neuroblastoma.


  • June L. Biedler, PhD, former Chairman, Cell Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering
  • Barbara A. Spengler, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

  • Biedler JL et al. (1976) A novel chromosome abnormality in human neuroblastoma and antifolate-resistant Chinese hamster cell lines in culture. Journal of the National Cancer Institute 57: 683-695 (PubMed ID: 62055)
  • Biedler JL et al. (1978) Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Research 38: 3751-3757 (PubMed ID: 29704)
  • Veas-Perez De Tudela M et al. (2010) Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase. Journal of Neurochemistry 113: 819-825 (PubMed ID: 20180881)

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

For internal research purposes by a commercial entity: Utilize MSK’s Express License, available here. In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. Please note: This license is only available for select cell lines, including this one.

To proceed, please download this contract, fill in all relevant fields, and email a scanned version to Alexandra Buga at  Once this license has been executed by MSK, you will receive a signed copy and invoice, and can then place your order with ATCC.

For licensing requests for a commercial purpose:  Contact Alexandra Buga, MS, MBA, Licensing Associate, Office of Technology Development, MSK, 646-888-1078,

For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354,

Stage of Development

Ready to use